Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 8/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663410 | 0.80 | HSD17B10 (0.41) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL3629414 | 0.79 | HSD17B10 (0.51) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL7665849 | 0.77 | HSD17B10 (0.43) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL7661033 | 0.77 | HSD17B10 (0.40) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL7672484 | 0.76 | HSD17B10 (0.39) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL3630522 | 0.76 | BUB1 (0.40) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL6767802 | 0.76 | ALPL (0.39) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL9803233 | 0.75 | HTT (0.44) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL7667971 | 0.74 | HSD17B10 (0.43) | HSD17B10ALPLMAPK1MEN1KMT2A | |
| SCHEMBL11393685 | 0.74 | ALPL (0.37) | HSD17B10ALPLMAPK1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | disclosed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2380879-B1 | Tetrahydroindolone and tetrahydroindazolone derivatives | ESANEX INC (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2380879-B1 | Tetrahydroindolone and tetrahydroindazolone derivatives | ESANEX INC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150329493-A1 | OMEGA-AMINO ACID DERIVATIVES OF BENZENE, PYRIDINE, AND PYRIDAZINE COMPOUNDS | HALL STEVEN E (US) | 2015-11-19 | — | — | US | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007101156-A1 | CYCLOHEXYLAMINO, BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | disclosed |
| CN-1896060-A | Tetrahydro-indolone and tetrahydro-indazolone derivatives and their use | GUOYAO LONGLI BIOLOG MEDICAL N (CN) | 2007-01-17 | — | — | CN | disclosed |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | ESANEX, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329493-A1 | OMEGA-AMINO ACID DERIVATIVES OF BENZENE, PYRIDINE, AND PYRIDAZINE COMPOUNDS | LTB4R, LTB4R2, PTGER4 | HSD17B10 3633/4885ALPL 3865/4885MAPK1 982/4885 |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | HRH4, P2RX4, CDK4 | HSD17B10 3529/4885ALPL 3314/4885MAPK1 1206/4885 |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | H1-5, NDUFS5, IL5 | HSD17B10 3696/4885ALPL 589/4885MAPK1 1872/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSD17B10 3780/4885ALPL 2081/4885MAPK1 1205/4885 |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | HSD17B10 1067/4885ALPL 4594/4885MAPK1 2027/4885 |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | HSF1, HSPA4, HSP90AB1 | HSD17B10 4158/4885ALPL 4849/4885MAPK1 314/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSD17B10 3780/4885ALPL 2081/4885MAPK1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.